IS1907B - Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm - Google Patents

Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm

Info

Publication number
IS1907B
IS1907B IS4972A IS4972A IS1907B IS 1907 B IS1907 B IS 1907B IS 4972 A IS4972 A IS 4972A IS 4972 A IS4972 A IS 4972A IS 1907 B IS1907 B IS 1907B
Authority
IS
Iceland
Prior art keywords
pharmaceutical composition
alzheimer
disease
preparation
treatment
Prior art date
Application number
IS4972A
Other languages
English (en)
Other versions
IS4972A (is
Inventor
Nikolas Gerolymatos Panayotis
Original Assignee
P.N. Gerolymatos S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by P.N. Gerolymatos S.A. filed Critical P.N. Gerolymatos S.A.
Publication of IS4972A publication Critical patent/IS4972A/is
Publication of IS1907B publication Critical patent/IS1907B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS4972A 1996-08-13 1999-02-10 Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm IS1907B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR96100286 1996-08-13
PCT/IB1997/000983 WO1998006403A1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
IS4972A IS4972A (is) 1999-02-10
IS1907B true IS1907B (is) 2003-12-16

Family

ID=10942479

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4972A IS1907B (is) 1996-08-13 1999-02-10 Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm

Country Status (25)

Country Link
US (1) US6001852A (is)
EP (1) EP0959888B1 (is)
JP (1) JP2000516606A (is)
KR (1) KR100489969B1 (is)
CN (1) CN1114407C (is)
AT (1) ATE205086T1 (is)
AU (1) AU720643B2 (is)
BR (1) BR9711194A (is)
CA (1) CA2264097C (is)
CZ (2) CZ295118B6 (is)
DE (1) DE69706566T2 (is)
DK (1) DK0959888T3 (is)
ES (1) ES2162319T3 (is)
HU (1) HUP9903906A3 (is)
IL (1) IL128416A (is)
IS (1) IS1907B (is)
NO (1) NO316768B1 (is)
NZ (1) NZ334124A (is)
PL (1) PL188838B1 (is)
PT (1) PT959888E (is)
RU (1) RU2193406C2 (is)
SI (1) SI0959888T1 (is)
SK (1) SK283117B6 (is)
TR (1) TR199900293T2 (is)
WO (1) WO1998006403A1 (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
DK1140090T3 (da) * 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
US6692234B2 (en) 1999-03-22 2004-02-17 Water Management Systems Pump system with vacuum source
CA2399136A1 (en) * 2000-02-09 2001-08-16 Hideo Kato 1h-imidazopyridine derivatives
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
JP4690043B2 (ja) 2002-10-04 2011-06-01 プラナ バイオテクノロジー リミティッド 神経に対し活性な化合物
US20080063599A1 (en) * 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
WO2005049026A1 (en) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Method and composition for treatment or prophylaxis of amyloidosis disorders
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
CN101073584B (zh) * 2005-10-14 2012-10-10 全面技术公司 改变细胞功能的方法和组合物
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8691224B2 (en) * 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
HRP20140240T4 (hr) * 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
CN101534826A (zh) 2006-04-14 2009-09-16 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性（amd）的方法
EP2046833B9 (en) * 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
MY153248A (en) * 2006-07-14 2015-01-29 Ac Immune Sa Humanized antibody against amyloid beta
RU2338542C1 (ru) * 2007-03-20 2008-11-20 Игорь Анатольевич Помыткин Применение воды с пониженным содержанием дейтерия для приготовления средств лечения нейродегенеративных заболеваний и улучшения когнитивной функции
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
EP2598882B1 (en) 2010-07-30 2017-07-26 AC Immune S.A. Safe and functional humanized antibodies for use in treating an amyloidosis
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
RU2642466C2 (ru) * 2013-04-02 2018-01-25 Аннцзи Фармасьютикал Ко., Лтд. Многофункциональные производные хинолина в качестве антинейродегенеративных агентов
EP4039255B1 (en) 2014-04-24 2025-10-15 Omoidesouzou Co. Ltd. Amyloid fiber formation limiter or inhibitor
KR20160057500A (ko) * 2014-11-05 2016-05-24 아카데미아 시니카 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE393238C (de) * 1923-05-12 1924-03-31 Maschb Akt Ges H Flottmann & C Bohrhammer
US3174899A (en) * 1960-12-30 1965-03-23 Ciba Geigy Corp Composition for the management of post antibiotic enteritis
US3178343A (en) * 1962-11-27 1965-04-13 Ciba Geigy Corp Pharmaceutical compositions and method of using same
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
RU2057531C1 (ru) * 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
GB9108080D0 (en) * 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
AU1831195A (en) * 1994-01-13 1995-08-01 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
WO1995031199A1 (en) * 1994-05-11 1995-11-23 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including h. pylori, infections and related diseases
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture

Also Published As

Publication number Publication date
HUP9903906A2 (hu) 2000-04-28
SK17999A3 (en) 1999-09-10
AU720643B2 (en) 2000-06-08
DE69706566D1 (de) 2001-10-11
SI0959888T1 (en) 2002-10-31
CZ48499A3 (cs) 1999-07-14
NO990595L (no) 1999-04-12
ATE205086T1 (de) 2001-09-15
IL128416A (en) 2004-06-01
PL331822A1 (en) 1999-08-02
CZ292411B6 (cs) 2003-09-17
NO316768B1 (no) 1999-04-12
AU3632497A (en) 1998-03-06
DE69706566T2 (de) 2002-07-11
DK0959888T3 (da) 2001-11-05
IL128416A0 (en) 2000-01-31
HUP9903906A3 (en) 2001-01-29
HK1022437A1 (en) 2000-08-11
CA2264097A1 (en) 1998-02-19
KR100489969B1 (ko) 2005-05-17
KR20000029958A (ko) 2000-05-25
CZ295118B6 (cs) 2005-05-18
ES2162319T3 (es) 2001-12-16
PT959888E (pt) 2002-02-28
PL188838B1 (pl) 2005-04-29
CA2264097C (en) 2007-11-27
NO990595D0 (no) 1999-02-09
BR9711194A (pt) 2000-01-11
SK283117B6 (sk) 2003-02-04
RU2193406C2 (ru) 2002-11-27
JP2000516606A (ja) 2000-12-12
CN1230115A (zh) 1999-09-29
WO1998006403A1 (en) 1998-02-19
IS4972A (is) 1999-02-10
CN1114407C (zh) 2003-07-16
TR199900293T2 (xx) 1999-06-21
US6001852A (en) 1999-12-14
EP0959888B1 (en) 2001-09-05
EP0959888A1 (en) 1999-12-01
NZ334124A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL133976A0 (en) Agents for the treatment of skin disorders
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
GB9103764D0 (en) Compositions
PT1007040E (pt) Utilizacao de fanquinona no tratamento da doenca de alzheimer
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
MX9707642A (es) Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos.
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
SE0001916D0 (sv) Novel formulation
BG106151A (en) Pharmaceutical complex
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
FI972637A0 (fi) K-ryhmän vitamiinin käyttö lisäkilpirauhasen liikatoiminnan hoitoon